TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), has released its 2024 Sustainability Report, showcasing meaningful environmental, social, and governance (ESG) achievements and reaffirming its commitment to conducting responsible, people-centered clinical research. 

Key 2024 ESG Highlights: 

• Reduced Scope 1 and 2 greenhouse gas emissions by 33%  
• Increased renewable energy use from 42% to 62% across global operations 
• Maintained EcoVadis Silver rating (69/100) for the fifth consecutive year
• Strengthened ESG reporting with reference to the Global Reporting Initiative (GRI) Standards and guided by the EU Corporate Sustainability Reporting Directive (CSRD) and European Sustainability Reporting Standards (ESRS)
• Sustained a “C” score from CDP, formerly the Carbon Disclosure Project, with Management-level recognition in several categories
• Maintained strong female representation across all levels, including leadership 
• Achieved high participation in performance reviews and professional development training 

In 2024, TFS advanced its ESG performance through deliberate actions, strengthening operational sustainability, supporting workforce development, and integrating ESG governance across business functions. The company’s efforts extend beyond metrics, supporting a research culture grounded in inclusivity, responsibility, and real-life impact. These efforts support TFS’s broader mission: to empower partners to advance treatments that promote health and well-being across the globe. 

“Sustainability is more than a framework at TFS; it’s a reflection of our values,” said Markus Granlund, CEO of TFS. “Our progress this past year was driven by the dedication of our employees and trusted partners, who make our mission a reality. From reducing emissions to creating an inclusive workplace, we are embedding ESG into the heart of how we operate—because when we do right by people and the planet, we stay true to our purpose and strengthen our impact.” 

TFS’s ESG commitment also extends beyond its operations to the communities and patients it serves. By aligning more closely with internationally recognized frameworks such as GRI, taking guidance from the CSRD/ESRS, and maintaining consistent third-party ratings, TFS ensures transparent, ethical, and forward-looking clinical research that supports long-term public health objectives. The company also continues to cultivate an inclusive and growth-oriented value chain, recognizing that fostering engagement, development, well-being, and diversity across its workforce and partners is key to delivering clinical excellence.  

“TFS’s dedication to sustainability reflects Ratos’ shared commitment to responsible growth and long-term value creation,” said Jonas Wiström, CEO of Ratos AB. “We are proud owners of TFS and are glad to be on this journey together, supporting greater ESG integration across the clinical research industry.”  

With continued focus on transparency, inclusivity, and long-term value creation, TFS remains committed to advancing sustainable clinical research to improve global health outcomes. The full 2024 Sustainability Report is available for download on the TFS HealthScience website: https://tfscro.com/sustainability/